TOP TEN perturbations for 39513_r_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39513_r_at
Selected probe(set): 227087_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39513_r_at (227087_at) across 6431 perturbations tested by GENEVESTIGATOR:

zalypsis study 2 / untreated OPM1 cell sample

Relative Expression (log2-ratio):-4.4280987
Number of Samples:2 / 2
Experimental zalypsis study 2
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated OPM1 cell sample
OPM1 multiple myeloma cells untreated.

OPM-1 / MM1.S

Relative Expression (log2-ratio):-3.8440905
Number of Samples:4 / 4
Experimental OPM-1
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-resistant. Synonyms:OPM1 Cellosaurus code:
Control MM1.S
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-sensitive. Parental cell line:: MM.1 Synonyms:MM.1S; MM1-S; MM-1S; MM1S Cellosaurus code:

F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):-3.3813143
Number of Samples:4 / 6
Experimental F. tularensis study 1 (tularensis Schu S4)
Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

IL-4; GM-CSF study 1 (early) / untreated monocyte sample

Relative Expression (log2-ratio):-3.0575829
Number of Samples:6 / 12
Experimental IL-4; GM-CSF study 1 (early)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 6 hours.
Control untreated monocyte sample
Freshly isolated human monocytes from healthy donors.

Langerhans cell histiocytosis study 1 / normal epidermal Langerhans cell sample

Relative Expression (log2-ratio):2.9804611
Number of Samples:7 / 3
Experimental Langerhans cell histiocytosis study 1
Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity.
Control normal epidermal Langerhans cell sample
Normal epidermal Langerhans cells were isolated from skin of healthy adult donors. Single cells were isolated by collagenase digestion from epidermal sheets and CD1a - expressing cells were isolated by FACS purification. Gene-chips were further analyzed for transcripts of potentially contaminating cells - no transcripts for CD3ε (T cell), CD19 (B cell) or Desmogleins 1-4 (keratinocytes) were detected, confirming purity of sorted cells.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):-2.9604092
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

HIV-associated neurocognitive disorder study 7 (normal) / HIV-associated neurocognitive disorder study 6 (normal)

Relative Expression (log2-ratio):2.929021
Number of Samples:2 / 2
Experimental HIV-associated neurocognitive disorder study 7 (normal)
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with normal brain pathology. The patients received antiretroviral therapy (ART).
Control HIV-associated neurocognitive disorder study 6 (normal)
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with normal brain pathology. The patients did not receive any antiretroviral therapy (ART).

PMA; ionomycine study 2 / unstimulated CD4 memory T-cell sample

Relative Expression (log2-ratio):-2.917901
Number of Samples:8 / 8
Experimental PMA; ionomycine study 2
CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 µg/ml). ATC code:---
Control unstimulated CD4 memory T-cell sample
Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects.

sangivamycin study 1 / untreated MCF-7 cell sample

Relative Expression (log2-ratio):-2.856432
Number of Samples:2 / 2
Experimental sangivamycin study 1
MCF7 cells treated with 2uM sangivamycin for 24 hours. ATC code:---
Control untreated MCF-7 cell sample
MCF-7 cells untreated.

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):-2.7979946
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---